1. Pink Sheet

Mifepristone Filing Supports 2023 US FDA Actions, But Experts Caution Against Overanalyzing

 
• By Sarah Karlin-Smith

Filing in the Whole Women’s Health mifepristone case defends the FDA’s 2023 decision on the abortion pill safety program, but experts warn it does not necessarily signal the Trump Administration position in other mifepristone cases attempting to restrict medication abortion access.

box of mifepristone tables on blue background
Filings in key mifepristone cases are being closely watched for signals that the Trump Justice Department will take a different approach than the Biden Administration. (Shutterstock)
Key Takeaways
  • The first significant legal filing in mifepristone litigation under the Trump Administration defends the FDA’s 2023 decision on its safety program.

The Trump Administration’s first significant legal filing in mifepristone litigation defends the US Food and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Litigation

More from Legal & IP